- Home
- ELTK vs CNTX Comparison
ELTK vs CNTX Comparison
Compare ELTK & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTK
- CNTX
- Stock Information
- Founded
- ELTK 1970
- CNTX 2015
- Country
- ELTK Israel
- CNTX United States
- Employees
- ELTK N/A
- CNTX N/A
- Industry
- ELTK Electrical Products
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ELTK Technology
- CNTX Health Care
- Exchange
- ELTK Nasdaq
- CNTX Nasdaq
- Market Cap
- ELTK 70.4M
- CNTX 78.0M
- IPO Year
- ELTK 1997
- CNTX 2021
- Fundamental
- Price
- ELTK $10.18
- CNTX $0.79
- Analyst Decision
- ELTK
- CNTX Strong Buy
- Analyst Count
- ELTK 0
- CNTX 5
- Target Price
- ELTK N/A
- CNTX $5.25
- AVG Volume (30 Days)
- ELTK 9.3K
- CNTX 145.6K
- Earning Date
- ELTK 08-14-2025
- CNTX 08-06-2025
- Dividend Yield
- ELTK 1.87%
- CNTX N/A
- EPS Growth
- ELTK N/A
- CNTX N/A
- EPS
- ELTK 0.45
- CNTX N/A
- Revenue
- ELTK $49,563,000.00
- CNTX N/A
- Revenue This Year
- ELTK $18.60
- CNTX N/A
- Revenue Next Year
- ELTK $9.04
- CNTX N/A
- P/E Ratio
- ELTK $22.55
- CNTX N/A
- Revenue Growth
- ELTK 6.75
- CNTX N/A
- 52 Week Low
- ELTK $7.65
- CNTX $0.49
- 52 Week High
- ELTK $12.19
- CNTX $2.70
- Technical
- Relative Strength Index (RSI)
- ELTK 46.22
- CNTX 58.08
- Support Level
- ELTK $10.20
- CNTX $0.68
- Resistance Level
- ELTK $10.45
- CNTX $0.73
- Average True Range (ATR)
- ELTK 0.35
- CNTX 0.05
- MACD
- ELTK -0.01
- CNTX -0.00
- Stochastic Oscillator
- ELTK 27.94
- CNTX 55.65
About ELTK Eltek Ltd.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.